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Metastatic cancer is extremely difficult to treat, and the presence of metastases greatly reduces a cancer 
patient’s likelihood of long-term survival. The ZEB1 transcriptional repressor promotes metastasis through 
downregulation of microRNAs (miRs) that are strong inducers of epithelial differentiation and inhibitors 
of stem cell factors. Given that each miR can target multiple genes with diverse functions, we posited that the 
prometastatic network controlled by ZEB1 extends beyond these processes. We tested this hypothesis using 
a mouse model of human lung adenocarcinoma metastasis driven by ZEB1, human lung carcinoma cells, 
and human breast carcinoma cells. Transcriptional profiling studies revealed that ZEB1 controls the expres-
sion of numerous oncogenic and tumor-suppressive miRs, including miR-34a. Ectopic expression of miR-34a 
decreased tumor cell invasion and metastasis, inhibited the formation of promigratory cytoskeletal struc-
tures, suppressed activation of the RHO GTPase family, and regulated a gene expression signature enriched 
in cytoskeletal functions and predictive of outcome in human lung adenocarcinomas. We identified several 
miR-34a target genes, including Arhgap1, which encodes a RHO GTPase activating protein that was required 
for tumor cell invasion. These findings demonstrate that ZEB1 drives prometastatic actin cytoskeletal remod-
eling by downregulating miR-34a expression and provide a compelling rationale to develop miR-34a as a 
therapeutic agent in lung cancer patients.
Introduction
Metastasis currently represents a tipping point in a cancer patient’s 
likelihood of achieving long-term survival. Metastatic deposits 
cannot be eradicated with any standard treatment options and are 
the most common cause of death from epithelial malignancies (1). 
Understanding the basic biological processes that govern metasta-
sis represents a critical barrier to attaining long-term survival for 
patients afflicted with epithelial cancer.
In one working hypothesis, metastasis is initiated by a popu-
lation of tumor cells that undergo epithelial-to-mesenchymal 
transition (EMT) in response to extracellular cues, leading to 
loss of polarized features, detachment from neighboring cells, 
increased motility, and invasion into surrounding matrix (2). 
Context-dependent cellular plasticity has been identified in 
side populations of established human cancer cell lines and 
in cell lines derived from mouse models of human epithelial 
cancers; these cells are marked by increased expression of alde-
hyde dehydrogenase or prominin-1 (CD133) (3, 4). The unique 
biological features of these cells and their dearth within pri-
mary tumors has led to the belief that they originate from rare 
populations of pluripotent cells or have uncommon gain-of-
function somatic mutations (5).
EMT is driven by several families of transcriptional repressors 
(ZEB, SNAIL, and basic helix-loop-helix factors) (6). ZEB factors 
contain 2 widely separated clusters of zinc fingers that bind to 
paired CAGGTA/G E-box–like promoter elements. They induce 
EMT by downregulating the expression of epithelial genes, includ-
ing E-cadherin (7, 8). During development, ZEB expression is 
upregulated in cells that undergo EMT and migrate by extracellular 
signals such as TGF-β and Notch ligands (9, 10). Beyond its physi-
ological roles, ZEB1 is overexpressed in many human cancers (e.g., 
prostate, colon, breast, and pancreatic) and has been implicated 
in metastasis and cellular events thought to precede it, including 
reduced expression of basement membrane components and induc-
tion of EMT (9). Increased ZEB1 levels correlate with poor progno-
sis in a variety of epithelial tumor types (11). In tumor cells, ZEB1 
represses the expression of certain microRNAs (miRs) — includ-
ing miR-183, miR-203, and miR-200 family members (miR-200a, 
miR-200b, miR-200c, miR-141, and miR-429) — that function not 
only as strong inducers of epithelial differentiation, but also as 
inhibitors of stem cell properties through repression of the stem 
cell factors SOX2, BMI1, and KLF4 (9). Reciprocally, miR-200 
family members directly target the ZEB1 3′–untranslated region 
(3′-UTR); hence, ZEB1 and miR-200 are interconnected through a 
double-negative feedback loop (12–15). The relevance of these find-
ings to metastasis is supported by findings in a mouse model of 
human lung adenocarcinoma driven by expression of Trp53R172HΔG 
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and KrasG12D alleles (KP mice) that recapitulates features of poor-
prognosis human lung adenocarcinomas, including overlapping 
oncogenic driver mutations, distribution of metastases, and gene 
expression signatures (16, 17). Metastatic tumor cell lines derived 
from these mice (KP cells) have high basal ZEB1 expression, form 
polarized epithelial spheres in 3D cultures, and undergo ZEB1-
dependent EMT in response to specific extracellular cues that can 
be reversed by ectopic expression of the miR-200b/a/429 cluster, 
whereas nonmetastatic KP cells have low basal ZEB1 expression 
and do not form spheres or undergo EMT (17). Thus, ZEB1 plays 
a key role in determining the metastatic fate of epithelial cancers.
Given that each miR downregulated by ZEB1 has the capacity to 
target multiple genes with diverse functions, we here posited that 
the scope of prometastatic biological processes controlled by ZEB1 
extends beyond EMT and stem-ness, testing this hypothesis in KP 
cells and human lung and breast carcinoma cells. Our findings 
showed that ZEB1 controlled an unexpectedly large miR network 
implicated in diverse cellular functions, activated the RHO family 
of GTPases, and enhanced the formation of promigratory cyto-
skeletal structures by downregulating miR-34a. We elucidated a 
gene expression signature regulated by miR-34a that was enriched 
in cytoskeletal functions and prognostic in human lung adeno-
carcinomas and revealed several miR-34a target genes, including 
Arhgap1, a RHO GTPase-activating protein (RHOGAP). Together 
with the known therapeutic effects of miR-34a on prostate tumors 
(18), these findings provide a strong rationale for developing 
miR-34a as a therapeutic agent to inhibit tumor growth and 
metastasis in lung cancer patients.
Results
ZEB1 regulates the expression of diverse miRs. Microarray-based inter-
rogation of global miR expression was carried out on a nonmeta-
static KP cell line (393P) that undergoes EMT and gains invasive 
and metastatic capabilities after ectopic ZEB1 expression (referred 
to herein as 393P_ZEB1 cells; GEO accession no. GSE38386). Zeb1 
levels in 393P_ZEB1 cells were 4-fold higher than in 393P_vector 
cells and were similar to endogenous ZEB1 levels in human lung 
cancer cell lines (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI63608DS1). Using 
393P_vector as the reference, we found that 46 miRs were differen-
tially expressed in 393P_ZEB1 cells: 27 downregulated (fold change 
less than 0.5, P < 0.01) and 19 upregulated (fold change greater than 
2.0, P < 0.01; Table 1 and Figure 1, A and B). Of the differentially 
expressed miRs, 19 were clustered within 7 genomic loci that are 
transcribed and processed together (Table 1). Quantitative RT-PCR 
(Q-PCR) analysis confirmed up- or downregulation of 14 of 16 miRs 
sampled, including 6 known direct transcriptional targets of ZEB1 
(miR-200a, miR-200b, miR-200c, miR-141, miR-429, and miR-203) 
and 8 other miRs not known to be regulated by ZEB1 (Figure 1C).
Several of the miRs regulated by ZEB1 function as oncogenes (e.g., 
miR-181b, miR-181d, and miR-10a) or tumor suppressors (e.g., miR-34a, 
miR-210, miR-326, miR-193a, miR-370, miR-206, miR-126, and 
miR-203), or lack reported roles in cancer development (e.g., miR-331, 
miR-605, miR-470, miR-581, and miR-351) (19–27). miR-34a was 
of particular interest as a candidate downstream mediator of ZEB1, 
given its tumor-suppressing activity in various models (18, 27) and 
prominent downregulation by ZEB1 (0.0015-fold; Table 1). In a panel 
of KP cell lines that have different basal Zeb1 levels, miR-34a levels cor-
related negatively with Zeb1 (R = –0.78; P = 1.9 × 10–9, 1-tailed Spear-
man rank correlation test) and positively with miR-200c (R = 0.78; 
Table 1
miRs regulated by ZEB1
miR Fold change P
Downregulated
miR-34a 0.0015 1.68 × 10–4
miR-210 0.0018 1.97 × 10–6
miR-326 0.0024 8.82 × 10–5
miR-224 0.0031 2.96 × 10–5
miR-193a 0.0033 2.03 × 10–4
miR-370 0.0038 3.03 × 10–4
miR-331 0.0047 1.36 × 10–4
miR-183A 0.0054 3.06 × 10–5
miR-96A 0.0064 1.35 × 10–4
miR-182A 0.0076 5.06 × 10–3
miR-141B 0.0093 8.66 × 10–4
miR-200bC 0.0112 1.34 × 10–3
miR-200cB 0.113 1.69 × 10–3
miR-200aC 0.0134 3.11 × 10–5
miR-206 0.0821 2.36 × 10–4
miR-148a 0.0857 6.26 × 10–3
miR-605 0.1092 9.35 × 10–3
miR-126 0.1559 6.82 × 10–3
miR-658 0.1945 3.24 × 10–3
miR-92b 0.2022 6.83 × 10–3
miR-467aD 0.2300 8.74 × 10–3
miR-297D 0.2441 8.49 × 10–3
miR-466D 0.2524 8.82 × 10–4
miR-203 0.3463 8.26 × 10–3
miR-429C 0.3530 1.68 × 10–3
miR-516-5p 0.4542 2.00 × 10–3
miR-555 0.4690 1.66 × 10–3
Upregulated
miR-470 187.4136 3.53 × 10–5
miR-581 40.5369 2.45 × 10–3
miR-542-3pE 21.2182 6.87 × 10–3
miR-351E 18.2156 8.59 × 10–3
miR-503E 10.8090 5.64 × 10–6
miR-324-5p 10.5958 4.22 × 10–3
miR-181a*F 10.2130 5.87 × 10–3
miR-140* 8.9735 1.85 × 10–3
miR-142-5p 8.3563 8.78 × 10–3
miR-181bF 8.1326 1.63 × 10–4
miR-99a 7.1670 6.81 × 10–3
miR-181aF 5.7037 7.13 × 10–4
miR-614 5.6733 1.86 × 10–4
miR-181dG 3.4967 8.03 × 10–3
miR-298 3.3597 2.86 × 10–3
miR-10a 3.0095 2.86 × 10–3
miR-344 2.9866 9.37 × 10–3
miR-185 2.4631 1.01 × 10–3
miR-181cG 2.0939 7.32 × 10–3
393P_ZEB1 and 393P_vector cells subjected to global miR profiling 
(Figure 1, A and B) to identify upregulated (>2-fold) or downregulated 
(<0.5-fold) miRs. A P value (2-tailed Student’s t test) less than 0.01 
was considered significant. AGenomic cluster with chromosomal loci 
Chr6:30,115,918–30,119,737. BGenomic cluster with chromosomal loci 
Chr6:124,667,932–124,668,408. CGenomic cluster with chromosomal 
loci Chr4:155,428,014–155,429,859. DGenomic cluster with chromosom-
al loci Chr2:10,397,969–10,437,548. EGenomic cluster with chromosomal 
loci ChrX:50,402,580–50,407,231. FGenomic cluster with chromosomal 
loci Chr1:139,863,032–139,863,295. GGenomic cluster with chromo-
somal loci Chr8:86,702,615–86,702,860.
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P = 2.9 × 10–9; Figure 2, A and B); similar findings were observed in a 
panel of 39 human lung cancer cell lines (Figure 2C).
Although located on a separate chromosome from miR-34a, 
expression of the miR-34b/c cluster is frequently coregulated with 
miR-34a (27, 28). However, TaqMan PCR assays confirmed the evi-
dence from our microarray studies (Figure 1) that ZEB1 downregu-
lated the expression of miR-34a, but not that of miR-34b or miR-34c 
(Supplemental Figure 2). Furthermore, miR-34a levels did not corre-
late with miR-34b or miR-34c in the panel of human lung cancer cell 
lines (Figure 2C). Collectively, these findings suggest that miR-34a 
expression is regulated through mechanisms different from those 
controlling the miR-34b/c cluster in the human and murine lung 
adenocarcinoma cells examined in this study.
ZEB1 downregulates miR-34a through ΔNp63. Although miR-34a is a 
known transcriptional target of p53 (27, 29), KP cells have the same 
germline Trp53 mutation, and the activity of p53 reporter constructs 
Figure 1
ZEB1 regulates the expression of numerous 
miRs. (A) Volcano plot depiction of findings from 
microarray analysis showing the miRs differentially 
expressed in 393P_vector and 393P_ZEB1 cells. 
The –log10 of P values (y axis) is plotted against 
the log2 of fold change between 2 groups (x axis). 
The size of the circle for each probe is proportional 
to the miR detection rate for the entire experiment. 
Each symbol is color coded according to average 
expression of the probe across the 2 groups (scale 
at right). Dotted lines delineate the cutoffs for miRs 
significantly downregulated (left) or upregulated 
(right) in 393P_ZEB1 cells. (B) Heat map depic-
tion of miRs differentially expressed in 393P_ZEB1 
cells (ZEB1), using 393P_vector cells (vec) as ref-
erence. (C) Taqman microRNA assays (Q-PCR) 
to confirm miRs differentially expressed by 
microarray. Data are mean ± SD (n = 3 samples). 
P values are indicated (2-tailed Student’s t test).
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was not different between 2 KP cell lines with high and low miR-34a 
levels (Figure 3A), which indicates that differential p53 activity does 
not contribute to relative miR-34a levels in KP cells. As an alternative 
intermediary, we turned our attention to ΔN isoforms of p63 (ΔNp63), 
which lack the transactivation domain and are transcriptional 
targets of ZEB1 in 393P cells (Supplemental Figure 3 and ref. 30). 
ΔNp63 acts in a dominant-negative fashion against p53, TAp63, and 
TAp73, but has been shown to function as a transcriptional activa-
tor of specific genes such as T and T2 (31). Murine embryonic fibro-
blasts (MEFs) deficient in all p63 isoforms had reduced miR-34a 
levels (Figure 3B), which suggests that p63 positively regulates miR-34a 
expression. On the basis of these findings in MEFs, we sought 
to determine whether ΔNp63 serves as an intermediate in ZEB1-
induced miR-34a repression in KP cells. Basal levels of ΔNp63 tran-
scriptional target genes T and T2 were higher in low-ZEB1 cell line 
393P than they were in high-ZEB1 cell line 344SQ, and introduc-
tion of ZEB1 into 393P cells decreased T and T2 levels (Figure 3C), 
which demonstrated that ZEB1 repressed ΔNp63 transcriptional 
activity. Ectopic ZEB1 expression downregulated ΔNp63 mRNA 
levels in 393P cells (Figure 3D), and siRNA-mediated knockdown of 
ZEB1 upregulated ΔNp63 mRNA levels in 344SQ cells (Figure 3E). 
The activity of a ΔNp63 promoter fragment (–1,128 to +109) was 
repressed by exogenous ZEB1, but not SNAI1 or TWIST1 (Figure 3F). 
Promoter deletion studies demonstrated that ZEB1 repressed the 
activity of a minimal ΔNp63 promoter fragment (–482 to +109) con-
taining 2 putative ZEB1-binding sites (E-boxes; Figure 3G), and site-
directed mutagenesis of the most proximal E-box element abrogated 
ZEB1-induced repression of the ΔNp63 promoter (Figure 3H).
We next examined whether ΔNp63 regulates miR-34a expression 
and acts directly on the miR-34a gene promoter in KP cells. Ectopic 
ΔNp63β expression in 344SQ cells upregulated miR-34a, but not 
miR-34b or miR-34c (Supplemental Figure 4), and increased the 
activity of a WT promoter, but not a mutant miR-34a promoter 
lacking a p53-binding site (Figure 3I). Binding of endogenous p63 
to the miR-34a promoter was examined by performing ChIP assays 
using an antibody that recognizes all p63 isoforms. In 344SQ cells, 
total p63 binding roughly reflected ΔNp63 binding, because ΔN 
isoforms were 67.0-fold more abundantly expressed than were TA 
isoforms (Supplemental Figure 5A). Murine keratinocytes were 
included as a positive control. The percentage of total p63 that 
bound to the p53/p63 site and to a nonspecific site in the miR-34a 
promoter was 0.19% and 0.06%, respectively (P = 0.08; Supplemen-
tal Figure 5B). To more specifically examine ΔNp63 binding to that 
site, ChIP assays were performed on 393P cells stably transfected 
with Myc-tagged ΔNp63. Using an anti-Myc antibody, we found the 
percentage of ectopic ΔNp63 that bound to the p53/p63 site and to 
a nonspecific site in the miR-34a promoter to be 0.39% and 0.17%, 
respectively (P = 0.002; Figure 3J). We concluded that ΔNp63 serves 
as an intermediate in ZEB1-induced miR-34a repression in KP cells.
miR-34a abrogates tumor cell invasion and metastasis and induces tran-
scriptional changes that are prognostic in human lung adenocarcinomas. 
To examine the biological role of miR-34a repression, miR-34a was 
Figure 2
miR-34a levels correlate tightly with the ZEB1/miR-200 axis. (A and B) Expression analysis of a panel of KP cell lines. (A) Log-scale cluster plots 
of normalized miR-200c and Zeb1 mRNA levels in 13 KP cell lines. Data are mean ± SD (n = 3 samples). 393P_ZEB1 and 393P_vector cells are 
included as controls. (B) Heat map representation of gene expression in A. (C) Expression analysis of a panel of human lung cancer cell lines. 
EMT marker expression in these 39 human cell lines was reported previously (17). Correlation (R and P, 1-tailed Spearman’s rank correlation 
test) is indicated for each gene relative to miR-34a.
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exogenously expressed under the control of a doxycycline-inducible 
promoter in 344SQ cells, which have high ZEB1 and low miR-34a 
expression (Figure 4A). Grown in monolayer, 344SQ_miR-34a 
cells proliferated at a rate similar to that of 344SQ_vector cells and 
demonstrated no biochemical evidence of apoptosis (Figure 4B 
and Supplemental Figure 6A). However, when grown in suspen-
sion, 344SQ_miR34a cells did not proliferate and demonstrated 
evidence of apoptosis (Supplemental Figure 6, B and C), which 
suggests that miR-34a enhanced the susceptibility of 344SQ cells 
to anoikis. 344SQ_miR34a cells exhibited reduced migration and 
invasion in Boyden chambers (Figure 4, C and D) and generated 
flank tumors in syngeneic mice that were smaller and metastasized 
to the lung less frequently (Figure 4E). Conversely, transfection of 
miR-34a hairpin inhibitor into 393P cells, which have low ZEB1 
and high miR-34a expression, induced a 84% decrease in endog-
enous miR-34a levels and 1.6- and 1.5-fold increases in cell migra-
tion and invasion, respectively (Supplemental Figure 7, A–C). In 
MDA-MB-231 human breast cancer cells and H1299 human lung 
cancer cells, which have high basal ZEB1 expression and undergo 
EMT in response to TGF-β (13, 32), overexpression of miR-34a 
antagonized migration and invasion (Figure 4F and Supplemen-
tal Figure 8, A–C), which was not a consequence of apoptosis or 
reduced proliferation (Supplemental Figure 8, D and E). There was 
no evidence of EMT reversal on the basis of expression of epithelial 
and mesenchymal markers in 344SQ cells and MDA-MB-231 cells 
(Figure 4, G and H). Thus, miR-34a downregulation was required 
for ZEB1-induced metastatic properties and apparently mediated 
these actions through EMT-independent mechanisms.
To gain insight into the biologic processes induced by miR-34a 
repression, microarray-based interrogation was carried out on RNA 
from tumor samples (344SQ_miR-34a and 344SQ_vector), which 
revealed a total of 805 genes that were differentially expressed (fold 
change greater than 1.5, P < 0.01; Supplemental Figure 9; GEO 
accession no. GSE38341). Q-PCR analysis of the same RNA samples 
confirmed differential expression of 22 of 24 genes sampled (Sup-
plemental Figure 10). The 512 downregulated genes were enriched 
in, among other Gene Ontology terms mitosis (P = 3.80 × 10–24, Fisher 
exact test), cell cycle (P = 3.40 × 10–23), mRNA processing (P = 4.72 × 10–10), 
and cytoskeleton (P = 3.04 × 10–7), whereas the 293 upregulated genes 
were enriched in protein dimerization activity (P = 7.55 × 10–4) and 
glutathione transferase activity (P = 1.12 × 10–3). Human lung adenocar-
cinomas for which both gene expression and clinical outcome data 
are publicly available (33–35) were scored based on the presence or 
absence of this 805-gene signature (high or low t score, respectively), 
as described previously (36); the absence of this expression signature 
in primary lung tumors correlated with poor prognosis in 3 inde-
pendent cohorts of lung cancer patients (Figure 4I). We conclude 
that the genes regulated by miR-34a are functionally diverse and 
have prognostic value in lung adenocarcinoma patients.
miR-34a inhibits promigratory cytoskeletal processes and attenuates 
RHO GTPase activity. Given the prominent effect of miR-34a on cell 
migration and invasion in Boyden chambers and the enrichment 
of the miR-34a transcriptome in cytoskeletal functions, we next 
carried out studies in 3D cultures to visualize tumor cell polariza-
tion and invasion. In Matrigel, 344SQ cells form hollow, polarized 
spheres with apical localization of ZO-1 and basolateral localiza-
tion of α6 integrin; these structures lose apical-basal polarity, 
become hyperproliferative, and form invasive membrane protru-
sions after TGF-β treatment (17). 344SQ_miR-34a and 344SQ_
vector cells formed hollow polarized spheres in the absence of 
TGF-β (Figure 5, A and C) and became aberrantly polarized and 
filled in their central cores after TGF-β treatment (Figure 5, 
B and D). However, TGF-β–treated 344SQ_vector structures 
formed invasive projections (Figure 5B), whereas 344SQ_miR-34a 
structures remained spherical in morphology (Figure 5D), despite 
upregulation of mesenchymal markers in both (Figure 5E). Thus, 
miR-34a abrogated TGF-β–induced formation of invasive cellular 
protrusions in spite of biochemical evidence of EMT.
We next carried out scratch injury assays to examine whether miR-34a 
regulates the formation of focal adhesions and promigratory mem-
branous protrusions. At the leading edge, 344SQ_vector cells formed 
lamellipodia with prominent filopodial extensions, whereas 344SQ_
miR-34a cells formed no filopodia (Figure 6A), generated more focal 
adhesions per surface area (mean, 232 versus 158; Figure 6B), and 
exhibited increased cell cross-sectional area (1,330 μm2 versus 410 μm2; 
Figure 6C). Consistent with these findings, 344SQ_miR-34a cells 
anchored more avidly to plastic (Figure 6D) and formed fewer col-
onies in soft agar (Figure 6E). In the larger panel of KP cell lines, 
anchorage avidity correlated positively with endogenous miR-34a 
levels (R = 0.6770; P = 0.0055, 1-tailed Pearson correlation test; 
Figure 6F). In MDA-MB-231 cells, exogenous miR-34a decreased cor-
tical F-actin–containing filopodial extensions and increased cell size 
without reversing mesenchymal features on the basis of ZO-1 local-
ization, which was predominantly cytoplasmic (Figure 6G). In con-
trast, exogenous miR-200b in MDA-MB-231 cells decreased filopodial 
extensions and shifted ZO-1 to a membranous distribution typical of 
a mesenchymal-to-epithelial transition (Figure 6G). Given the central 
role of RHO GTPases in actin cytoskeletal remodeling (37, 38), we quan-
tified activated (GTP-bound) RHO family members after treatment 
with promigratory cytokines, which revealed that ectopic miR-34a 
expression in 344SQ cells attenuated EGF- or TGF-β–induced 
increases in GTP-bound CDC42, RAC1, and RHO (Figure 6, H and I). 
Thus, miR-34a increased cellular adhesions, attenuated cytokine-
induced RHO GTPase activation, and inhibited formation of mem-
brane protrusions and migration in response to external stimuli.
Figure 3
ZEB1 downregulates miR-34a levels through ΔNp63. (A) Luciferase 
reporter assays on KP cells cotransfected with p53 or empty expres-
sion vectors and reporters containing promoters from Mdm2, 14-3-3σ, 
or consensus p53-binding sites (Generic). Results are expressed rela-
tive to empty vector transfectants, set at 1.0. (B) Q-PCR analysis of 
miR-34a in WT or Trp63-null (p63–/–) MEFs. (C) Q-PCR values relative 
to 344SQ cells (left) and 393P_ZEB1 cells (right), set at 1.0. (D and E) 
Q-PCR values relative to 393P_vector cells (D) and control siRNA-
transfected 344SQ cells (E), set at 1.0. (F) Location of putative E-boxes 
in the ΔNp63 promoter are shown above ΔNp63 promoter luciferase 
assays on cotransfected 393P cells. (G) ΔNp63 promoter reporter 
constructs are shown above luciferase activities in cotransfected 
393P cells, expressed relative to basal reporter activity (set at 1.0). 
(H) ΔNp63 promoter constructs are WT or lack 1 (Mut-a and Mut-b) 
or 2 (Mut-a/b) proximal E-boxes. Luciferase activities in cotransfected 
393P cells are also shown, expressed relative to basal reporter activity 
(set at 1.0). (I) Luciferase reporter constructs that do (Mut) or do not 
(WT) contain a site-directed mutation in a p53-binding site. Lucifer-
ase activities in cotransfected 393P cells are also shown, expressed 
relative to basal reporter (GL3) activity (set at 1.0). (J) DNA amount at 
specific (p53/p63) and nonspecific (NS) sites of the miR-34a promoter 
precipitated from transiently transfected 393P cells by anti-Myc anti-
body, corrected for nonspecific binding activity by IgG precipitation and 
expressed as percent p63 bound. P values were determined by 2-tailed 
Student’s t test. Data are mean ± SD (n = 3).
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Figure 4
miR-34a regulates multiple biological properties of tumor cells. (A–D) 344SQ_miR-34a cells and 344SQ_vector cells were cultured in the pres-
ence or absence of doxycycline (Dox). (A) Q-PCR analysis of miR-34a levels. (B) Cell numbers in monolayer. Migrating (C) and invading (D) 
cells in Boyden chambers were photographed and counted. Scale bars: 100 μm. (E) Primary tumor weight and total lung metastases from flank 
tumors in syngeneic mice (mean ± SD, n = 5). P values were determined by 2-tailed Student’s t test. (F) MDA-MB-231 cells were transiently 
transfected with a random sequence miR precursor molecule control or with pre–miR-34a precursor. Shown are Q-PCR analysis of miR-34a 
levels, expressed relative to control transfectants (set at 1.0), and migration and invasion assays in Boyden chambers. (G and H) Q-PCR analysis 
of epithelial (Cdh1 and Scrib) and mesenchymal (Cdh2 and Vim) markers and their transcriptional regulators (Zeb1, Zeb2, Snai1, Snai2, and 
Twist1) in 344SQ_vector and 344SQ_miR-34a cells (G) and in MDA-MB-231 cells transiently transfected with pre-miR control or pre–miR-34a 
precursor (H). Results are expressed relative to control transfectants (set at 1.0). Data are mean ± SD (n = 3). *P < 0.01. (I) Kaplan-Meier analysis 
of 3 independent cohorts of lung cancer patients (33–35), comparing the differences in risk between tumors with high (>0) or low (<0) scores 
(36), reflecting the presence or absence, respectively, of overlap with the murine miR-34a signature. P values from log-rank (differences between 
arms) and univariate Cox (gene signature score as a continuous variable) tests are shown.
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Arhgap1 is a miR-34a target gene required for the regulation of RHO 
GTPase activity and tumor cell invasion. We next examined whether 
miR-34a inhibits RHO GTPases at the level of GTP loading or 
upstream at the level of focal adhesion kinase (FAK), which is auto-
phosphorylated at Tyr397 and initiates RHO GTPase activation 
after recruitment to ligand-bound EGFR (39). Arguing against 
the latter possibility, EGF-induced FAK-Tyr397 phosphorylation 
was unchanged by exogenous miR-34a, as determined by Western 
blot analysis (data not shown). At the level of GTP loading, RHO 
GTPases cycle from inactive (GDP-bound) to active (GTP-bound) 
states by binding to guanine nucleotide exchange factors (GEFs), 
and in the reverse direction by binding to GAPs (37). To examine 
whether miR-34a directly targets GEFs or GAPs, we used a predic-
tion algorithm (TargetScan; http://www.targetscan.org) to scan 
the genome for putative miR-34a binding sites and discovered sites 
in the 3′-UTR of a RHOGAP (Arhgap1) and a CDC42 downstream 
effector (Cdc42se1) (Figure 7A). Reporter assays were carried out to 
determine whether miR-34a binds directly to these 3′-UTRs as well 
as those of other predicted miR-34a target genes identified in our 
analysis that are not directly involved in RHO GTPase regulation, 
but are potentially important in tumorigenesis (Figure 7B). Rela-
tive to its effect on a negative con-
trol 3′-UTR (Flt1), cotransfection of 
miR-34a precursors repressed 
3′-UTRs of Arhgap1 by 59%, Satb2 (a 
regulator of chromatin structure; ref. 
40) by 47%, Lef1 (a regulator of Wnt 
signaling; ref. 41) by 44%, and Hnf4a 
(a known miR-34a target; ref. 42) by 
37%, but did not affect other report-
ers (Figure 7B). Site-directed muta-
genesis of 2 predicted binding sites 
in the Arhgap1 3′-UTR with differing 
PCt values (0.71 and <0.1) revealed 
that miR-34a suppressed Arhgap1 
3′-UTR reporter activity through the 
conserved binding site, but not the 
nonconserved site (Figure 7C).
In the KP cell line panel, ARHGAP1 
and miR-34a levels correlated nega-
tively (R = –0.7692; P = 0.0021, 1-tailed 
Spearman rank correlation test; Fig-
ure 7D), and exogenous miR-34a 
decreased ARHGAP1 levels in 344SQ 
cells (Figure 7E). Conversely, trans-
fection of miR-34a hairpin inhibitor 
into 393P cells induced a 2.0-fold 
increase in ARHGAP1 expression 
(Supplemental Figure 11A). In 
MDA-MB-231 and H1299 cells, 
ectopic miR-34a downregulated 
ARHGAP1 (Figure 7F and Supple-
mental Figure 11B). To determine 
whether ARHGAP1 downregulation 
recapitulates the effects of miR-34a, 
ARHGAP1 was depleted by introduc-
tion of shRNAs (Figure 8A), which 
increased basal levels of GTP-bound 
CDC42 and RAC1 (Figure 8B), 
attenuated EGF-induced levels of 
GTP-bound CDC42 and RAC1 (Figure 8B), reduced invasive pro-
jections on tumor spheres after TGF-β treatment (Figure 8C), and 
increased cell adherence (Figure 8D).
The anti-invasive effect of Arhgap1 shRNA was paradoxical, given 
that RHO is required for proinvasive actin cytoskeletal remodeling. 
We performed experiments to confirm this finding and to deter-
mine whether ARHGAP1 is required for miR-34a–induced pheno-
typic features. ARHGAP1 expression was reconstituted in 344SQ_
miR-34a cells through stable transfection of an Arhgap1 cDNA 
expression vector (Figure 8E), and the 344SQ_miR-34a/ARHGAP1 
double transfectants were compared with 344SQ_miR-34a/vector 
cells from the standpoint of basal and cytokine-induced RHO 
activity and invasive activity. ARHGAP1 reconstitution repressed 
basal GTP-bound CDC42 and rescued TGF-β–induced sphere 
invasion in Matrigel (Figure 8, F and G), which suggests that 
miR-34a represses TGF-β–induced tumor cell invasion by down-
regulating ARHGAP1. However, ARHGAP1 reconstitution did 
not restore RHO activation in response to EGF or TGF-β treat-
ment (Figure 8F) or rescue tumor growth or metastasis (data not 
shown), which suggests that these phenotypic effects of miR-34a 
are mediated through other target genes.
Figure 5
miR-34a blocks invasion, but does not reverse EMT. (A–D) miR-34a repressed TGF-β–induced inva-
sion in 3D Matrigel cultures. 344SQ_vector cells formed polarized epithelial spheres (A) that became 
hyperproliferative and invasive in the presence of TGF-β (B). 344SQ_miR-34a cells formed polarized 
epithelial spheres (C) that did not become invasive in the presence of TGF-β (D). Shown are light (left) 
and fluorescent (right) microscopic images of structures formed after 10 days in Matrigel containing 
doxycycline in the presence or absence of TGF-β (10 ng/ml). Blue, Topro-3; red, anti–α6 integrin; 
green, anti–ZO-1. Scale bars: 200 μm (light); 50 μm (fluorescent). (E) miR-34a did not abrogate TGF-β–
induced EMT. Q-PCR analysis of epithelial markers (Cdh1, Scrib, and Crb3) and mesenchymal mark-
ers (Cdh2 and Vim) and their transcriptional regulators (Zeb1, Zeb2, Snai1, and Snai2) in 344SQ_vec-
tor and 344SQ_miR-34a cells after 10 days in Matrigel cultures containing doxycycline in the presence 
or absence of TGF-β. Results are expressed relative to empty vector transfectants treated without 
TGF-β (set at 1.0). Data are mean ± SD (n = 3).
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miR network that targets RHO GTPases and their associated GEFs 
and GAPs (53). Examples include RHOA (miR-31, miR-133, and 
miR-155), RHOC (miR-138 and miR-10b), CDC42 (miR-29), TIAM1 
(miR-10b), and ARHGDIA (miR-151) (53). Here we showed that 
miR-34a inhibited cytokine-induced RHO family GTPase activa-
tion and discovered that a RHOGAP, Arhgap1, was a miR-34a tar-
get gene. ARHGAP1 reconstitution in miR-34a–overexpressing 
cells did not rescue RHO activation in response to EGF or TGF-β 
treatment, which was expected, given that RHOGAPs inhibit RHO 
GTPase activity. However, TGF-β–induced invasion was abrogated 
in metastasis-prone tumor cells by ARHGAP1 depletion and was 
rescued in miR-34a–overexpressing cells by ARHGAP1 reconstitu-
tion. The proinvasive effect of ARHGAP1 was paradoxical, given 
that RHO GTPase activity stimulates the formation of actin cyto-
skeletal structures that drive cell migration. Although the mecha-
nism is unclear, ARHGAP1 binds to a number of proteins other 
than RHO family GTPases — including BNIP2, SRC, UBC, and 
PIK3R1 (BioGRID; http://thebiogrid.org) — that regulate diverse 
biological processes and may have contributed to the proinvasive 
effect of ARHGAP1 through RHO GTPase–independent mecha-
nisms. Collectively, these findings suggest that ARHGAP1 mediates 
some, but not all, of the biological effects of miR-34a (Figure 8H).
We discovered that ZEB1 regulated a larger number of miRs 
than had previously been reported (12, 13, 15). This multiplicity 
was due in part to 19 miRs clustered within 7 genomic loci that 
are transcribed and processed together. ZEB1 downregulated cer-
tain miRs and upregulated others, which could be related either 
to the capacity of ZEB1 to function as a transcriptional repressor 
or activator (54–56) or to indirect regulation of miRs by ZEB1. 
In support of the latter possibility, we found that ZEB1 indirect-
ly repressed miR-34a through ΔNp63. The reported biological 
functions of the 46 miRs were diverse, encompassing hypoxic 
response (miR-210), cell differentiation (miR-326), proliferation 
(e.g., miR-224, miR-206, miR-542-3p, and miR-126), apoptosis 
(miR-96, miR-193a, and miR-181a), and migration (miR-206, 
miR-503, and miR-181b), among other functions (Supplemental 
Table 1), which indicates that ZEB1 might control a number of 
biological processes by regulating the expression of these miRs.
The p63 transcription factor family plays a central role in the 
regulation of embryonic development, normal adult tissue homeo-
stasis, and malignancy (57). The tumor-suppressive properties of 
TAp63 are exerted through the upregulation of a wide variety of 
miRs, including let-7, miR-15/16a, miR-145, miR-129, miR-26, 
miR-30, and miR-146a (57). Senescence in keratinocytes is activated 
through ΔNp63-induced downregulation of miR-138, miR-181a, 
miR-181b, and miR-130b (58). TAp63 is also a transcriptional acti-
vator of Dicer, an endoribonuclease required for miR biogenesis 
(29). The findings presented here build on this growing body of 
evidence that miRs are central mediators of the diverse biological 
actions of p63 by showing that miR-34a was upregulated by ΔNp63 
and was a potent tumor suppressor in a Kras/Trp53-driven lung 
adenocarcinoma model. Furthermore, our finding that ΔNp63 
served as a downstream mediator of ZEB1 completes a feedback 
circuit initiated by p63, which transcriptionally activates the 
miR-200b/a/429 cluster (59) and, in turn, directly targets ZEB1 (9, 
13, 14), thereby relieving the ZEB1-induced repression of ΔNp63 
shown here. There are numerous other p63/miR circuits, includ-
ing one involving miR-193-5p, which targets p63 and is directly 
repressed by p63 (60). Thus, miR homeostasis is tightly regulated 
through multiple mechanisms involving p63 and ZEB1.
Discussion
Studies using experimental tumor models have established a 
strong link between high levels of EMT activators and loss of cell 
polarity, reduced expression of basement membrane components, 
and increased propensity for metastasis (43–47). The discovery 
that EMT activators endow epithelial tumor cells with pluripo-
tency led to the current belief that metastatic propensity is directly 
related to plasticity in response to extracellular cues (12, 48–50). 
Here, positing that the scope of prometastatic biological processes 
controlled by ZEB1 extends beyond EMT and stem-ness, we dis-
covered that ZEB1 drove promigratory cytoskeletal processes and 
metastasis by downregulating the expression of miR-34a. Exoge-
nous miR-34a decreased tumor cell invasion and metastasis, inhib-
ited the formation of promigratory cytoskeletal structures, sup-
pressed activation of the RHO GTPase family, and regulated a gene 
expression signature that was enriched in cytoskeletal functions 
and prognostic in human lung adenocarcinomas. Biological repro-
gramming of this magnitude supports a central role for miR-34a 
in metastasis regulation by ZEB1.
RHO family members play key parts in the regulation of actin 
cytoskeletal remodeling and tumorigenesis. RAC1 is required for 
the development of primary lung adenocarcinomas in mice that 
express mutant KRAS (51). The activities of RHO, RAC1, and 
CDC42 are coordinated to regulate membrane protrusions and 
cell-matrix adhesions at the leading edge of migrating cells to con-
trol forward movement (52). Effectors of RHO GTPases include 
RHO-associated protein kinase, focal adhesions, and membrane 
protrusions, which together mediate cell adhesion to extracellular 
matrix, link matrix attachments to intracellular signaling path-
ways, and drive actomyosin contractility and cell locomotion (52). 
Beyond these roles, a large body of evidence implicates RAC1 in 
the assembly, disassembly, and maintenance of adherens junctions 
and tight junctions, which play a central role in the regulation of 
apical-basal polarity (52). Tightly regulating these processes is a 
Figure 6
miR-34a regulates actin cytoskeletal remodeling and RHO family 
GTPase activity. (A–C) Cells imaged at leading edge of scratch-wound-
ed confluent cultures. (A) Filopodia (arrows) formed in 344SQ_vector, 
but not 344SQ_miR-34a, cells. Brackets denote lamellipodia. (B) Focal 
adhesions in anti-vinculin–stained cultures, counted per defined sur-
face area of confluent cells (circles) using ImageJ. Data are mean ± SD 
(n = 10). Red, phalloidin; green, vinculin. (C) Cells were outlined (white 
lines), and their surface areas were measured using ImageJ. Data 
are mean ± SD (n = 20 [344SQ_vector]; 12 [344SQ_miR-34a]). (D) 
Attached cells were quantified 1, 2, or 3 hours after seeding by opti-
cal densitometry (595 nm) of cells stained with crystal violet. Data are 
mean ± SD (n = 3). *P < 0.01. (E) Cells seeded in soft agar were stained 
with nitrotetrazolium blue 3 weeks after seeding, and colonies larger 
than 100 μm in diameter were counted. Data are mean ± SD (n = 3). 
(F) Attached cells were quantified by optical densitometry 3 hours after 
seeding and expressed relative to miR-34a levels from Figure 2A. Cor-
relation (R and P, 1-tailed Pearson’s correlation test) is indicated. (G) 
MDA-MB-231 cells transiently transfected with control, miR-34a, or 
miR-200b precursors and imaged under fluorescence (blue, DAPI; red, 
phalloidin; green, anti–ZO-1). As a comparison, miR-200b–transfected 
cells demonstrated mesenchymal-to-epithelial transition. (H and I) 
Western blot analysis of GTP-bound (CDC42-GTP) and total (CDC42) 
RHO family GTPases. Phospho-ERK1/2 (H) and phospho-SMAD3 (I) 
were included as positive controls for EGF- and TGF-β–induced signal-
ing, respectively. Scale bars: 50 μm (A, B, and G); 100 μm (C); 500 μm 
(E). See complete unedited blots in the supplemental material.
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miRs locally or systemically to the tumor tissue where they regulate 
their target genes (62, 63). Physical and chemical moieties of the 
particles that facilitate the targeted distribution and the controlled 
and sustained release of miRs are under clinical investigation (64). 
External moieties, such as aptamers and ligands that enhance miR 
uptake by cancer cells, are being developed to direct the particles to a 
particular tissue (65, 66). Moreover, efforts are underway to initiate 
clinical trials that deliver miRs into patients with advanced cancer.
Methods
Antibodies and plasmid constructs. Antibodies against ERK, phospho-ERK, 
SMAD3, phospho-SMAD3, PARP, cleaved caspase-3 (Cell Signaling Tech-
nology), ACTIN (Sigma-Aldrich), p63 (Abcam), and ARHGAP1 were pur-
chased (Santa Cruz Biotechnologies). Doxycycline (Sigma-Aldrich), EGF 
(Invitrogen), and TGF-β (Calbiochem) were purchased. Human SNAI1 
cDNA (catalog no. 16218), murine Twist1 cDNA (catalog no. 1783; Add-
gene), murine Arhgap1 cDNA, and murine Arhgap1 shRNA (Origene) were 
purchased. To construct the miR-34a overexpression vector, a tet opera-
tor–H1 promoter fusion (tH1) was cloned into the XmnI and BamHI sites 
of pENTR2B (Invitrogen). A 487-nt fragment containing miR-34a (∼200 nt 
either side of the mature miR) was amplified from human cDNA by PCR 
and directionally cloned into the BamHI and EcoRI sites of pENTR2B-tH1. 
The pLV711G lentiviral expression construct contains a Gateway cassette 
(Invitrogen) and the regulatory protein (T-REx) under the control of the 
The evidence presented here that miR-34a is a potent repressor 
of tumor growth and metastasis in a mouse model of human lung 
cancer bolsters evidence from other mouse models that miR-34a is 
a promising therapeutic agent. Delivery of miR-34a oligomers sys-
temically by tail vein inhibits tumor growth in mice bearing lung 
adenocarcinomas, suppresses metastasis to the lung and other 
organs, and prolongs the survival of mice bearing orthotopic human 
prostate carcinomas (61). The mechanisms by which miR-34a exerts 
its therapeutic effects are tumor cell type specific. For example, in 
the lung adenocarcinoma metastasis model shown here, miR-34a 
downregulation enhanced promigratory cytoskeletal processes, 
but was not required for stem cell features, based on formation of 
polarized epithelial spheres, whereas it targets the stem cell marker 
CD44 in prostate cancer cells and represses stem-ness in prostate, 
glioblastoma, pancreatic, and gastric cancer cells (18, 49). The dis-
tinct mechanisms by which miRs exert tumor suppressor functions 
in a given tumor type might be leveraged to create combinatorial 
treatment approaches. In metastatic KP cells, the miR-200 family 
members and miR-34a are all sharply downregulated, and ectopic 
expression of the miR-200b/a/429 cluster locks KP cells into an epi-
thelial state and abrogates metastasis (17). Thus, combined delivery 
of miR-34a and miR-200 family members might be complemen-
tary in these cells. Safe and efficient approaches using lipid-based 
nanoparticles (neutral or charged) have been developed that deliver 
Figure 7
Arhgap1 is a miR-34a target gene. (A) 3′-UTRs analyzed. Shown are size (right) and location of predicted miR-34a binding sites. Poorly conserved 
sites were defined on the basis of criteria established by TargetScan. mut1 and mut2, mutations generated in 2 putative miR-34a binding sites in the 
Arhgap1 3′-UTR. Flt1 3′-UTR is a negative control. (B and C) miR-34a–induced repression of 3′-UTR reporters. Luciferase assays on 344SQ cells 
transiently cotransfected with the indicated 3′-UTR reporters and control or miR-34a precursors. Data are mean ± SD (n = 3). *P < 0.001; #P < 0.01. 
(D) Correlation of miR-34a levels in KP cell lines (from Figure 2A), with densitometric analysis of ARHGAP1 protein expression by Western analysis. 
ACTIN was used as a loading control. Correlation (R and P, 1-tailed Spearman rank correlation test) is indicated. (E) miR-34a downregulated ARHGAP1. 
Western blot analysis of ARHGAP1 in 344SQ_vector and 344SQ_miR-34a cells. Densitometric analysis (numbers below ARHGAP1 gel) is shown 
relative to 344SQ_vector cells (set at 1.0). (F) Q-PCR analysis of ARHGAP1 mRNA levels in MDA-MB-231 cells 72 hours after transient transfection 
with pre-miR negative control or pre–miR-34a precursors. Data are mean ± SD (n = 3). P values were determined by 2-tailed Student’s t test. See 
complete unedited blots in the supplemental material.
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later. For migration and invasion assays, 1 × 105 cells were cultured in the 
upper wells of Transwell and Matrigel chambers, respectively (BD Biosciences), 
and allowed to migrate toward 10% FBS in the bottom wells. After 16 hours 
of incubation, migrating or invading cells were stained with 0.1% crystal 
violet, photographed, and counted. Cellular proliferation was measured in 
anchorage-dependent and -independent conditions by counting cells seeded 
onto high- or low-adherence plates, respectively (Greiner Bio-One), using the 
Countess automated cell counter (Invitrogen). For immunocytochemistry, 
cells were cultured on collagen-coated coverslips and then stained with DAPI 
(Sigma-Aldrich), Alexa Fluor 568–conjugated phalloidin (Invitrogen), and 
anti-vinculin (Millipore) antibody. Cells were cultured in 3D Matrigel cultures 
(BD Biosciences) and stained with immunofluorescently tagged antibodies, as 
described previously (17). A Zeiss LSM 510 confocal microscope was used to 
EF-1a promoter (67). Gateway technology (Invitrogen) was used for the 
transfer of miR-34a into the pLV711G vector to create a single lentiviral 
vector enabling doxycycline-responsive expression of miR-34a.
Cell culture studies. Murine (307P, 344LN, 344P, 344SQ, 393LN, 393P, 412P, 
531LN1, 531LN2, 531LN3, 531P1, 531P2, and 713P) and human lung can-
cer cells (H2009 and H1299) were cultured in RPMI 1640 (Mediatech) with 
10% FBS (Sigma-Aldrich) in the presence or absence of 1 μg/ml doxycycline 
(Sigma-Aldrich). WT and p63–/– murine embryonic fibroblasts (MEFs) were 
maintained in DMEM (Mediatech) with 10% FBS. MDA-MB-231 cells were 
cultured in Leibovitz’s L-15 (Mediatech) with 10% FBS. Cells were transfected 
using Dharmafect-DUO (Dharmacon). For soft agar assays, 5 × 104 cells (in 
0.3% agar) were seeded into 6-well plates layered with 0.8% agar, and colonies 
were stained with 0.5 mg/ml nitrotetrazolium blue (Sigma-Aldrich) 21 days 
Figure 8
ARHGAP1 mediates specific phenotypic effects of miR-34a. (A) Western blot analysis of ARHGAP1 in 344SQ cells stably transfected with 
scrambled shRNA (scr) or 1 of 4 Arhgap1 shRNAs (shA, shB, shC, or shD). ACTIN was used as loading control. (B) Western blot analysis of 
GTP-bound (-GTP) and total RHO family GTPases. (C) Spheres formed by scrambled shRNA– and Arhgap1 shB–transfected 344SQ cells after 
10 days in 3D Matrigel cultures in the presence or absence of TGF-β (10 ng/ml). Scale bars: 100 μm. (D) Attached cells were quantified by optical 
densitometry 3 hours after seeding. Data are mean ± SD (n = 3). P values were determined by 2-tailed Student’s t test. (E) Western blot analysis 
of 344SQ_miR-34a cells stably transfected with Flag-tagged ARHGAP1 cDNA or empty vector using antibodies against ARHGAP1 (top), Flag 
(middle), or ACTIN as a loading control (bottom). Arrows at top denote locations of endogenous (ARHGAP1) and ectopic (Flag-ARHGAP1) 
ARHGAP1. (F) Western blot analysis of GTP-bound and total CDC42 in 344SQ_miR34a/vector and 344SQ_miR34a/ARHGAP1 cells treated 
for 10 minutes with or without EGF or TGF-β. (G) 344SQ_miR34a/vector and 344SQ_miR34a/ARHGAP1 cells were cultured for 10 days in 
Matrigel in the presence or absence of TGF-β and photographed under phase-contrast microscopy. TGF-β induced loss of lumen formation in 
both transfectants, but invasive projections formed only in 344SQ_miR34a/ARHGAP1 cells. Scale bars: 50 μm. (H) Proposed model illustrating 
the ARHGAP1-dependent and -independent phenotypic effects of miR-34a. See complete unedited blots in the supplemental material.
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(68). p63-DNA complexes were diluted 10-fold in ChIP dilution buffer and 
incubated overnight at 4°C with 2 μg anti–pan-p63 antibody (4A4; Abcam) 
or 2 μg IgG. Resulting chromatin was resuspended in 300 μl double-dis-
tilled H2O. The percent DNA bound was calculated as (2ΔCt × 2.5)p63 antibody − 
(2ΔCt × 2.5)IgG, where ΔCt is Ctinput chromatin − Ctsample.
Western blotting. Cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, and protease/phosphatase inhibi-
tors (Sigma-Aldrich). Cell lysates were separated by SDS-PAGE, transferred 
onto PVDF membrane, and then incubated with primary antibodies and 
HRP-conjugated secondary antibodies. Protein bands were visualized with 
Pierce ECL Western Blotting substrate (Thermo). RAC1, CDC42, and RHO 
activation assay kits (Upstate) were used for GTPase assays.
Animal husbandry. Syngeneic (129/Sv) mice (n = 5 per group) were injected 
subcutaneously in the right flank with 344SQ cells (1 × 106 per mouse) that 
had been stably transfected with miR-34a or empty vectors. Mice were treat-
ed with doxycycline (2 mg/ml) in drinking water (2% sucrose), monitored 
daily for tumor growth, sacrificed at 6 weeks, and necropsied to isolate pri-
mary tumors and sites of metastasis, which were confirmed histologically 
by analysis of hematoxylin and eosin–stained, formalin-fixed tissues.
Affymetrix gene expression profiling. Total RNA was extracted from primary 
tumors from mice injected with 344SQ_vector and 344SQ_miR-34a cells 
using RiboPure kit (Ambion), and then hybridized to Affymetrix GeneChip 
Mouse Genome 430 2.0 array (Asuragen). Data processing and determi-
nation of differentially expressed genes were carried out essentially as 
described previously (69). Transcriptomic data sets were deposited in GEO 
(accession no. GSE38341).
Statistics. With the exception of mRNA and miR profiling, data were ana-
lyzed using 2-tailed Student’s t test and Spearman rank correlation test. A 
P value less than 0.05 was considered significant.
Study approval. All mouse studies were approved by the IACUC at the Uni-
versity of Texas MD Anderson Cancer Center. Mice received standards of 
care and were euthanized according to the standards set forth by the IACUC.
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capture fluorescent images of Matrigel cultures. Fluorescence-stained slides 
depicting filopodia, lamellipodia, and focal adhesions were imaged on a Nikon 
Ti microscope equipped with a CoolSnap HQ2 camera (Photometrics). Image 
stacks of 100-nm sections were then deconvoled with Autoquant (Media 
Cybernetics). For attachment assays, 1 × 105 cells were seeded on 24-well plates 
and incubated for 1–3 hours. After washing with PBS twice, attached cells were 
stained with 0.1% crystal violet, and optical density was measured at 595 nm.
miR expression profiling. Total RNA was isolated from 393P_vector and 
393P_ZEB1 cells, profiled using the DiscovArray platform by Asuragen, 
and analyzed as described previously (17). The platform included all but 
91 of the 1,086 probes in the Sanger miRBase version 9.2 covering humans, 
rats, and mice and an additional 12,894 exploratory probes covering mul-
tiple other species. Transcriptomic data sets were deposited in GEO (acces-
sion no. GSE38386). Heat maps were generated using Cluster and Tree-
View software (http://rana.lbl.gov/EisenSoftware.htm).
Quantitative RT-PCR (Q-PCR). Total RNA was isolated from the cells 
using TRIzol (Invitrogen) according to the manufacturer’s protocol. To 
analyze mRNA levels, Q-PCR assays were performed after reverse transcrip-
tion with Superscript III reverse transcriptase (Invitrogen) using a SYBR-
Green–based system (Applied Biosystems). mRNA levels were normalized 
on the basis of mRNA for ribosomal protein L32 (Rpl32). See Supplemental 
Table 2 for primer sequences. miR levels were quantified using Taqman 
microRNA assays (Applied Biosystems) according to the manufacturer’s 
protocol and normalized on the basis of snoRNA-135.
Luciferase reporter assays. Cells were seeded on 24-well plates (1 × 105 cells/
well) 1 day before transfection, and then transfected with 500 ng luciferase 
reporter plasmids and 50 ng hRL-control vector. After 48 hours, lucifer-
ase activity was measured using Dual-Luciferase Reporter Assay System 
(Promega). A murine miR-34a promoter region was isolated by PCR from 
TC-1 murine ES cell genomic DNA and ligated into the pGL3-basic vector 
(Promega). p53-reporter plasmids (Mdm2, 14-3-3σ, and generic promoters) 
were gifts from M.-H. Lee (University of Texas MD Anderson Cancer Center, 
Houston, Texas, USA), and the ΔNp63 and TAp63 promoter reporters were 
gifts from I. Shachar (Weizmann Institute of Science, Rehovot, Israel). For 
the 3′-UTR assay, murine 3′-UTRs were amplified by PCR from genomic 
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